Absence of Variation in Health Care
As we try to identify key causes of high US healthcare costs, the topic of variation, specifically variation in practice style, often emerges. It is an accepted fact that in manufacturing quality [...]
Plan Design Considerations for Self-Funded Employers
Unlike insurers whose plans must comply with strict metal tier and essential health benefit requirements, self-funded groups benefit from flexibility of plan design and offerings. However, most of the time this freedom [...]
Thoughts on Kaiser Acquiring Geisinger
A former colleague came across an article I wrote last year, 'My Recent Experience with Kaiser Health System' – Axene Health Partners, LLC. After reading the article, she reached out to ask my [...]
Biosimilars: Maximizing Adoption
To achieve savings benefits from the coming wave of biosimilars, biosimilars must be adopted by prescribers, members, and payers (through their formulary strategies). While previous biosimilar launches have produced some initial savings [...]
It’s a Bird! It’s a Plane! No, Just Another Healthcare Disruptor!
As with many things in life, change is challenging, often undetected when it starts, many times mislabeled as an aberration, but always important. As John F. Kennedy once said, “Change is the [...]
Biosimilars: Payer Decision Making
Once the first Humira biosimilar, Amjevita, launched in the United States in January, payers needed to begin making decisions about coverage not only for Amjevita but for all the other Humira biosimilars [...]
Any views or opinions presented in these articles are solely those of the author and do not necessarily represent those of the company. AHP accepts no liability for the content of these articles, or for the consequences of any actions taken on the basis of the information provided unless that information is subsequently confirmed in writing.